This Week's Biotech Catalysts
All FDA decisions, clinical trial readouts, and key events happening this week.
10
Total Events
2
PDUFA Dates
5
Trial Readouts
Monday
March 2327Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
Tuesday
March 2413Wednesday
March 2529Centanafadine Hydrochloride Phase 3 Results Expected
Thursday
March 2631IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. Phase 2 Results Expected
Friday
March 27No events scheduled
SaturdayToday
March 28No events scheduled
Sunday
March 29No events scheduled
Receive a summary of upcoming biotech catalysts every Monday morning.
Why Track Weekly Biotech Catalysts?
Biotech stocks are driven by binary events - FDA decisions, clinical trial results, and regulatory milestones. Knowing which catalysts are coming this week helps investors prepare for potential volatility and trading opportunities.
Key Events to Watch
- PDUFA Dates: FDA target action dates for drug approvals
- Clinical Trials: Phase 1, 2, and 3 data readouts
- AdCom Meetings: FDA Advisory Committee votes
- Conferences: Medical conference presentations
Stay Informed
This page updates automatically as new events are added or outcomes are announced. Bookmark it or sign up for our weekly email digest to never miss an important catalyst.